iPSC-derived microglia offer a powerful tool to study microglial homeostasis and diseaseassociated inflammatory responses. Yet, microglia are highly sensitive to their environment, exhibiting transcriptomic deficiencies when kept in isolation from the brain. Furthermore, species-specific genetic variations demonstrate that rodent microglia fail to fully recapitulate the human condition. To address this, we developed an approach to study human microglia within a surrogate brain environment. Transplantation of iPSC-derived hematopoieticprogenitors into the postnatal brain of humanized, immune-deficient mice results in contextdependent differentiation into microglia and other CNS macrophages, acquisition of an ex vivo human microglial gene signature, and responsiveness to both acute and chronic insults. Most notably, transplanted microglia exhibit robust transcriptional responses to A-plaques that only partially overlap with that of murine microglia, revealing new, human-specific Aresponsive genes. We therefore propose that this chimeric model can provide a powerful new system to examine the in vivo function of patient-derived and genetically-modified microglia.
INTRODUCTION
Microglia play critical roles in sculpting brain development, modulating neural plasticity, and maintaining homeostasis (Salter and Stevens, 2017; Stevens et al., 2007; Wu et al., 2015) . As the primary immune cell of the central nervous system (CNS), microglia are highly responsive, reacting rapidly to local injury, neuroinflammation, and a multiplicity of brain pathologies (Nimmerjahn et al., 2005; Perry and Holmes, 2014) . Recent genetic studies have further highlighted the importance of these cells in disease, with the discovery of many polymorphisms in microglial-enriched genes associated with a variety of neurological disorders including Alzheimer's disease (AD), frontotemporal dementia, amyotrophic lateral sclerosis, autism, and schizophrenia (Karch et al., 2014; Salter and Stevens, 2017) . However, despite these important findings, experimental platforms that enable systematic analyses of human microglia in vivo, and the effects of genetic variability on microglia function within the brain, have yet to be realized.
1 While transgenic mouse models have provided invaluable tools for examining the role of microglia in these disorders, rodents cannot fully recapitulate the growing complement of human genetic variability implicated in these polygenic diseases (Dawson et al., 2018; Friedman et al., 2018; Ueda et al., 2016) . Fortunately, the ability to generate induced pluripotent stem cells (iPSCs) from patients, and then differentiate iPSCs into defined cell subtypes, has generated exciting opportunities to examine the relationships between complex genetic backgrounds and disease-associated phenotypes. The recent development of methods to differentiate iPSCs into microglia has further allowed researchers to begin unraveling the contribution of microglial risk genes to human disease (Pocock and Piers, 2018 ). Yet, while these protocols have provided researchers with the ability to generate an abundance of human microglia in vitro, a recent study has highlighted that microglia, as highly plastic cells, undergo dramatic alterations when maintained outside of the brain environment, exhibiting numerous changes in gene expression within hours to days of transfer to culture conditions (Gosselin et al., 2017) . Unfortunately, many of these in vitrorelated transcriptional programs are mirrored in iPSC-derived microglia, demonstrating an important limitation to the modeling of microglial biology in a cell culture environment. Overall, this suggests that experiments utilizing in vitro microglia to model disease states may present an incomplete picture of their genetic state or how they respond to stimuli, presenting a major roadblock to a deeper and more complete understanding of in vivo microglial biology.
To begin to address this challenge, we and others performed initial experiments to determine the feasibility of transplanting human microglia or hematopoietic stem cells (HSCs) into the brains of immunodeficient mice (Abud et al., 2017; Bennett et al., 2018; Capotondo et al., 2017) . Yet, to date no studies have thoroughly examined and validated the phenotype, transcriptional profile, and functional responses of engrafted human microglia to injury or disease-associated pathology, steps that are critical for determining the applicability of this approach. Toward this goal, we present the development and validation of a chimeric model system that allows researchers to examine iPSC-derived human microglia in the context of the living mammalian brain.
RESULTS

Human iPSC-derived hematopoietic progenitor cells engraft and differentiate into cells expressing mature microglia markers
Given the developmental ontogeny of microglia, which arise from yolk sac-derived primitive hematopoietic progenitor cells (HPCs) (Prinz et al., 2017) , we hypothesized that transplantation of iPSC-derived HPCs (iHPCs), as generated in McQuade et al. (2018) which express multiple genes associated with primitive HPCs (Figure 1A) , into the early postnatal MITRG brain would result in robust engraftment of human cells that would differentiate into mature microglia. To test this, we transplanted GFP-expressing iHPCs directly into the lateral ventricles and overlying cortex of P1 MITRG mice (Rongvaux et al., 2014) (Figure 1B) . After allowing the mice to age for two months, immunohistochemical (IHC) analysis revealed robust engraftment of human cells throughout the forebrain that strongly expressed the homeostatic microglial marker P2RY12 (Figure 1C) , IBA1 (Figure S1A) , the myeloid transcription-factor PU.1 (Figure S1B) , and the brain resident microglia-specific marker TMEM119 along with the human nuclei marker Ku80 (Figure S1C) . Further analysis revealed a high degree of concordance between the expression of GFP and P2RY12 (Figure 1D-G) as well as the complex, ramified morphology adopted by the transplanted iHPCs (Figure 1H-I) suggesting that the iHPCs had differentiated towards a microglial fate.
Assessment of the distribution of the xenotransplanted microglia (xMGs) throughout the mouse brain revealed variation depending on the distance from the site of transplantation. In areas that were directly targeted by human iHPC injection, robust xMG engraftment was observed along with very few host murine microglia (Figure S2A) . In contrast, more distant regions displayed typical distribution and tiling of murine microglia with only an occasional xMG (Figure S2B) . Quantification of microglia within the targeted regions, including the cortex, hippocampus, and striatum, demonstrated that ~80% of the PU.1+ microglia coexpressed the human-specific nuclear marker Ku80 (Figure 1J-K) . Furthermore, no significant differences in engraftment were observed between different batches of iHPC transplants (F 1,18 =0.6923, p=0.4163) , across different brain regions (F 2,18 =1.462, p=0.2580) , or in the interaction between iHPC batch and region (F 2,18 =0.4417, p=0.6497) (Figure 1K ) demonstrating the reproducibility of this approach. Additionally, comparison of this paradigm to the methodology presented in our previous study (Abud et al., 2017) , which transplanted mature iMGLs into the adult MITRG brain, clearly demonstrated a marked increase in engraftment with P1 HPC transplantation (Figure S2C-D) .
Expression of human CSF1 is necessary and sufficient for the long-term engraftment of human microglia in the murine brain.
We previously demonstrated that human microglia could survive for at least 2 months following transplantation into adult MITRG immune-deficient mice (Rag2 KO, IL2rγ KO) (Abud et al., 2017) . However, we remained curious as to whether all three humanized genes present in the MITRG; hCSF1, hCSF2, or Thrombopoietin (hTPO) (Rongvaux et al., 2014) , were necessary for xMG survival. Given the importance of CSF1R signaling for microglia survival, and previous reports that the murine CSF1 ligand cannot fully activate human CSF1R signaling (Elmore et al., 2014; Rathinam et al., 2011; Sieff, 1987) , we hypothesized that expression of humanized CSF1 alone was necessary for robust engraftment of human microglia in the murine brain. To test this, we performed transplantations of GFP + iHPCs into MITRG mice ( Figure S2E ) and MITRG mice which had the humanized hCSF2 and hTPO genes bred out (Figure S2F) , revealing virtually identical engraftment of human cells in both strains and confirming that expression of hCSF2 and hTPO is not necessary for xMG survival. In stark contrast, no xMGs were detected in mice that expressed hCSF2 and hTPO but lacked hCSF1 expression ( Figure S2G) . Interestingly, the necessity for hCSF1 was also dosedependent, as heterozygous hCSF1 mice exhibited partial survival of xMGs ( Figure S2H) . Lastly, transplantations into the parental mouse strain from which the MITRG model was developed (JAX# 017708), which includes Rag2/IL2rγ deletion and hCSF1 but lacks hCSF2 and hTPO, demonstrated that human iHPCs differentiate into microglia which engraft at levels that are consistent with transplantation into MITRG mice (Figure S2I) . Taken together, these data demonstrate that human CSF1 is both necessary and sufficient to enable the long-term engraftment and survival of human microglia in the mouse brain.
Transplanted iHPCs acquire altered morphologies and phenotypic signatures in a niche-dependent manner
xMGs were observed throughout the forebrain and had adopted characteristic, regionspecific distributions, morphologies, and marker expression levels. For example, within the cortex and olfactory bulb, xMGs created a mosaic network of ramified cells that tiled neatly with neighboring microglia, establishing distinct microdomains (Figure 2A-C) . Within the hippocampus and overlying corpus collosum, a less uniform pattern was observed, with ramified GFP + /P2RY12 + cells appearing within CA1, and more elongated microglia expressing lower levels of P2RY12 within the overlying white matter of the corpus callosum ( Figure 2D ).
In addition, relatively few xMGs were observed within the granule cell layer (Figure 2E) , a hippocampal subregion that exhibits the lowest number of microglia (De Lucia et al., 2016; Shapiro et al., 2009) . Within the striatum (Figure 2F) , xMGs engrafted predominantly within the gray matter, avoiding the white matter bundles, again consistent with the typical distribution of microglia within this region (Savchenko et al., 2000) . Interestingly, limited engraftment of GFP + /P2RY12 + xMGs could also be observed far from the transplantation sites, including parts of the cerebellum (Figure 2G ) and the spinal cord, where xMGs adopted a more linear, less ramified morphology (Figure 2H) .
In addition to these varying populations of P2RY12 + xMGs, we also observed subsets of human cells that expressed GFP yet lacked P2RY12 expression, instead exhibiting morphology, localization, and markers typical of other CNS-myeloid cells (Figure 2I-T) . This finding suggests that transplanted iHPCs maintain the potential to differentiate into the other yolk sac-derived CNS-myeloid cell types: perivascular (pvMϕ), meni ), meningeal (mMϕ), meni ), and choroid plexus (cpMϕ), meni ) macrophages. GFP + /P2RY12 -pvMϕ), meni -like cells were found along the vasculature, in close opposition to GLUT1-expressing murine blood vessel endothelial cells (Figure 2I-K) . These pvMϕ), meni -like cells also exhibited colocalized expression of CD163 (Figure 2L) , an established marker of non-microglial CNS myeloid cells (Goldmann et al., 2016) . Whole meningeal mounts ( Figure 2M ) confirmed engraftment of more amoeboid GFP + /P2RY12 -mMϕ), meni -like cells which were also observed in sections where the meninges were preserved during cryosectioning (Figure 2N-O) . As with the pvMϕ), meni -like cells, these meningeal-localized cells also expressed CD163 ( Figure 2P) . Additionally, an occasional population of GFP + /P2RY12 -/CD163 + cells was found within the choroid plexus (Figure 2Q-T) . The relatively small number of cpMϕ), meni -like cells is consistent with the understanding that cpMϕ), meni s are maintained in the adult brain through a partial turnover from definitive bone marrow hematopoietic stem cells, whereas microglia, pvMϕ), meni , and mMϕ), meni continually self-renew (Prinz et al., 2017) . Overall, these results suggest that transplantation of iHPCs into the early postnatal brain permits the context-dependent maturation of microglia and other CNS myeloid cells.
xMGs acquire a transcriptomic signature that closely resembles in vivo human microglia
While IHC analysis revealed that xMGs expressed many microglial markers and adopted the morphology of homeostatic microglia, an in-depth transcriptomic analysis of multiple cell lines was needed to test whether xMGs fully acquire a microglial fate. Therefore, we developed a method to recover pure populations of xMGs, derived from fluorescent and nonfluorescent iPSC lines, from transplanted brains in order to perform RNA-sequencing ( Figure  S3 ). To assess xMGs in comparison to human, brain-derived microglia, the transcriptome was compared between xMGs, microglia collected from fresh human tissue (ExVivo), human microglia that had been cultured (InVitro), and iMGLs, which had been differentiated from iPSCs entirely in vitro (Table S1). To further increase the power of our comparisons, these samples were bioinformatically compared to a previously published dataset (Gosselin et al., 2017) that included additional ExVivo and InVitro samples (Table S1).
To explore the overall similarities and differences between these 49 human microglial samples, we performed principal component analysis (PCA) after correcting for a labdependent batch effect (Figure S4A-B ; Table S2 ). Following pre-filtering of lowly expressed genes, PCA analysis of the remaining transcriptome (16,413 genes) revealed a clear separation of microglia groups based on environment, with a high degree of clustering between the brain-derived xMGs and ExVivo microglia ( Figure 3A) . However, as we were primarily interested in determining if transplantation had induced an in vivo transcriptomic profile, we next used the dataset published by Gosselin et. al. to define a list of 3,432 braindependent microglial genes that were differentially expressed between the ExVivo and InVitro samples (Table S3 ). PCA analysis with this gene list further enhanced clustering of xMGs with ExVivo microglia, whereas iMGLs and InVitro microglia formed distinct, segregated clusters, demonstrating that in vivo differentiation of iHPCs within the murine brain induces a brain-dependent microglia transcriptome ( Figure 3B) .
In order to perform an enhanced, gene-level analysis, the brain-dependent genes were filtered by the 881-gene microglial signature published by Gosselin et al., resulting in 190 brain-dependent signature genes (Figure 3C) . Euclidean clustering of the samples mirrored the PCA clustering, with iMGLs and InVitro groups on one branch and the xMGs and ExVivo samples intermixed within the other branch ( Figure S4C) . However, while the xMG profile was highly similar to the ExVivo signature, differential gene expression (DGE) analysis between xMGs and ExVivo samples demonstrated that 96 of the 881 signature genes were differentially expressed (Table S3, Figure S4D ). Interestingly, Euclidean clustering of all in vivo samples using these 96 differentially expressed genes revealed that, while xMGs clustered separately from most of the ExVivo samples, the three youngest ExVivo samples were intermixed with the xMG samples ( Figure S4E ). This finding potentially suggests that xMGs have yet to fully mature at the examined time points. However, there were also a number of MHC Class II genes ( Figure S4D ) that were expressed at higher levels in the older ExVivo samples, possibly indicating an increased activation state. One explanation could be that xMGs were isolated from the healthy mouse brain whereas the ExVivo samples were isolated from patient tissue affected by epilepsy or collected from tumor margins, resulting in an activated state. Longer-term aging studies may provide the evidence needed to understand these small, albeit intriguing, differences.
Further gene-level analysis showed that transplantation into the brain environment induced a number of important microglia gene sets. Key microglia-associated transcription factors, including EGR1, FOS, FOSB, JUN, KLF2, KLF4, and SALL1 (Figure 3D) , that were either not expressed or lowly expressed in vitro, were fully recovered following transplantation. We also focused on a number of microglia genes that have been proposed to be important for homeostasis or activation (Keren-Shaul et al., 2017; Krasemann et al., 2017) , as it has been suggested that microglia derived from transplanted cells can exhibit an 'activated' profile (Bennett et al., 2018) . With regards to homeostatic genes such as CX3CR1, P2RY12, SELPLG and TGFB1, xMG expression is similar to that of the ExVivo samples, with xMGs displaying slightly elevated expression ( Figure 3E) . In contrast, xMGs do not appear to present with increased expression of genes that have been implicated in microglia activation states including CLEC7A, CST7, IL21R, or SIGLEC1. Additionally, whereas in vitro iMGLs express very low levels of TMEM119, transplantation fully recovers expression, consistent with the recent demonstration that TMEM119 is a brain-dependent microglia gene (Bennett et al., 2016) ( Figure 3E) .
Finally, as we are interested in utilizing this model to study microglia responses to AD pathology, we compiled a list of AD risk genes to ensure that xMGs were not aberrantly expressing these transcripts. As with the previous analyses, xMGs presented with an expression profile closely mirroring that of the ExVivo samples ( Figure 3F) . Notably, genes of current interest in the field such as APOE, TREM2, BIN1, PLCG2, MS4A4A and MS4A6A, are expressed at ExVivo levels. These findings, in conjunction with the previously presented transcriptomic profiling, not only suggest that xMGs have the potential to be utilized in future disease studies but also, considering the human iPSC origin of these cells, offer a level of genetic similarity to human microglia that cannot currently be matched by other approaches. xMGs survey the local environment and rapidly respond to focal brain injury While validating the morphological, histological, and transcriptomic properties of human microglia within the rodent brain was critical, the utility of this chimeric approach is also dependent on whether xMGs can accurately recapitulate microglial function in vivo. Therefore, we utilized 2-photon microscopy to visualize the in vivo behavior of GFP + xMGs. Live imaging of xMGs revealed an array of neatly tiled, highly ramified human cells that were actively surveying their immediate environment (Figure 4A, VideoS1) , as evidenced by constant extension and retraction of processes at rates consistent with endogenous murine microglia ( Figure 4B) . Based on previously reported descriptions of endogenous murine microglia behavior (Nimmerjahn et al., 2005) , these observations are highly consistent with the activity and morphology of homeostatic microglia.
Since xMGs appeared to be actively surveying the brain parenchyma, we next sought to challenge that behavior with a localized, parenchymal injury. Due to the limited availability of in vivo, functional microglia data from humans, we concentrated our analysis on focal laser ablation, an approach that has been used to induce a highly reproducible microglial response in mice (Davalos et al., 2005; Nimmerjahn et al., 2005) . We again used 2-photon imaging to visualize xMGs in the immediate vicinity of the damage site as well as those distally located to the damage site and microglial response was monitored for up to 50 minutes post-injury ( Figure 4C-D) . In concordance with previously characterized murine microglial responses, laser damage elicited a rapid and highly localized response in which xMGs within 40m of the damage site immediately responded by sending processes to assess the injury, while distal xMGs showed no obvious deviations from homeostatic surveillance activity (Video S2). Accordingly, quantification of mean GFP intensity within the damage site showed a steady increase for 30 minutes post-injury followed by a sustained intensity for up to 50 minutes of imaging, whereas distal GFP intensity remained consistent across all timepoints ( Figure 4D) . Importantly, the extension rate and magnitude of this human microglial injury response is similar to that of murine microglia ( Figure 4E ) (Davalos et al., 2005; Nimmerjahn et al., 2005) , indicating that xMGs respond to local CNS injury in a manner that is consistent with in vivo microglia.
xMGs phagocytose neuronal components after brain trauma
In several murine models, repeat mild closed head injury (rmCHI) has been shown to induce sustained microglial activation and interaction with neurons post injury (Gold et al., 2018; Shitaka et al., 2011) . Thus, to determine if xMGs can interact with murine neuronal components, mice were exposed to rmCHI two months post-transplantation and histological assessment of the injury site was performed 8-weeks later (Figure 4F-G) . Low-power images reveal that GFP + xMGs infiltrated the injury site ( Figure 4F) , while higher-power imaging revealed that lysosomes (CD68; blue) within GFP + xMGs colocalized with β3-tubulin (red), indicative of phagocytosis of neuronal microtubule components and debris (Figure 4G ; white arrows indicate colocalization of CD68 and β3-tubulin). Thus, xMGs can readily interact with and phagocytosis degenerating neurons.
xMGs respond robustly to a systemic inflammatory challenge
Our next functional assessment focused on characterizing the xMG response to a commonly used peripheral immune challenge that mimics systemic bacterial infection: lipopolysaccharide (LPS). Mice transplanted with GFP + iHPCs were aged 2 months and then administered either saline or LPS via intraperitoneal injection. Quantification of IHC images revealed a significant reduction in the homeostatic marker P2RY12 following LPS treatment 6 and, conversely, a significant upregulation of CD45 (Figure 5A-C) , consistent with an LPSinduced increase in microglial activation state. Interestingly, LPS also induced increased GFP expression, likely because of the activating effect of inflammatory stimuli on CMV-based promoters such as the CAG promoter used to drive GFP expression (Figure 5A-C) (Varley et al., 1995) .
In addition to the observed morphological and protein-level changes, xMGs were isolated from saline and LPS-treated mice in order to examine transcriptomic alterations. DGE analysis revealed that LPS treatment resulted in 607 up-regulated and 287 down-regulated genes (Figure 5D , Table S4 ). As anticipated, several of the highly upregulated genes (e.g. TMEM176A/B, IL21R, SPP1, MSR1, TLR2) are involved in cytokine recognition, phagocytosis, and pathogen responses while many downregulated genes (e.g. P2RY12, P2RY13, ITGAM, SELPLG) are typical markers of microglia homeostasis. Further assessment of gene ontology via gene set enrichment analysis (Subramanian et al., 2005 ) demonstrated a coordinated upregulation of pathways related to immune response, antigen presentation, and translation initiation (Figure S5A -C, Table S4 ). Additionally, examination of the differentially expressed xMG signature genes from Figure S4D showed that many genes were normalized toward ExVivo levels following LPS treatment, including some of the previously noted MHC Class II genes (Figure S5D , red text). This finding lends some preliminary support to our aforementioned hypothesis that, rather than being immature, xMGs transplanted into the healthy mouse brain may present with a less activated profile than microglia isolated from disease-affected human tissues.
The response of human microglia to systemic inflammation cannot be accurately modeled in vitro.
Many studies regarding microglia responses to LPS have been performed in vitro, by treating murine or human microglia directly with LPS (Abud et al., 2017; Pulido-Salgado et al., 2018) . We therefore decided to recapitulate this approach by treating iMGLs made from the same GFP + cell line as the LPS-exposed xMGs, with LPS in vitro. RNA-seq and DGE analysis revealed 888 up-regulated genes and 679 down-regulated genes following in vitro LPS treatment (Table S5 ). Compared to the in vivo results of 607 up-regulated and 287 downregulated genes, it was immediately clear that the response to LPS in a dish was more dramatic than the response in vivo. Correlation analysis between saline and LPS samples from both environments demonstrated limited correlation between in vitro and in vivo groups, with the least correlated groups being in vivo LPS and in vitro LPS (Figure 5E) . Unsurprisingly, the lack of correlation further manifested as a limited overlap between the DGE lists, with the LPS groups only sharing 22.7% of the up-regulated genes and an abysmal 4% of down-regulated genes ( Figure 5F ). To determine if these gene-level differences also manifested at the pathway level, we performed gene ontology (GO) analysis, which similarly revealed very little overlap between the two environments ( Figure 5G , Table S5 ).
Transitions in the expression profile of xMGs are orchestrated by well-established microglial transcriptional regulators
An overarching goal of our approach was to develop a predictive experimental model that could be used to study human microglia in vivo. Therefore, we next sought to perform an unbiased analysis of the two environmental transitions that we had exposed human microglia to: one from in vitro to in vivo and another from in vivo to peripheral stimulation with LPS. We began by performing DGE analysis, to assess how these transitions altered the transcriptional state of xMGs, and then utilized k-means clustering (Lloyd, 1982) to identify 8 clusters of genes with expression profiles that were unique to each of the states (Figure 6A , Table S6 ). Exemplifying the powerful predictive potential of this approach, a subsequent literature-based search of all differentially expressed genes revealed that a large majority of these genes are highly relevant to microglial biology ( Figure 6A) . Likewise, many of these genes have been implicated in AD (Hickman et al., 2018) . Next, we performed GO analysis to determine which gene classes changed in response to each transition (Figure 6B) . Comparison of GO terms revealed that when xMGs undergo transplantation, genes related to synapse assembly, exploratory behavior, and cell-cell adhesion are strongly induced, all of which would be predicted to increase following xMG integration into the brain. In contrast, GO terms associated with genes that were upregulated following peripheral LPS stimulus were instead consistent with immune activation, interferon response, antigen presentation, and a hallmark of in vivo microglia activation: zinc homeostasis (Kauppinen et al., 2008) .
To further test if the observed expression signatures were influenced by known microglial gene regulatory factors, we performed an unbiased search to identify transcription factor (TF) motifs enriched within the promoter regions of all genes that exhibited differential expression with each transition state (Figure 6C , Table S6 ). Using this approach, we were able to identify several TF motifs that were highly enriched during the in vitro to in vivo transition and known to be critical regulators of microglial homeostatic function (e.g. RUNX2, MEF, JUN, FOS, KLF) . Similar analysis on the xMG+LPS samples identified unique TF motifs that have been implicated in the transformation of microglia to an activated state (e.g. IRF8, STAT3, RelA, CEBPA, MTF-1).
xMGs adjacent to beta-amyloid plaques exhibit a Disease Associated Microglia (DAM)-like phenotype
Since we had confirmed that xMGs were capable of appropriately responding to both exogenous and endogenous inflammatory insults, we next sought to determine if xMGs could be utilized in a disease modeling application. As it was recently reported that murine microglia transition into distinct and highly specialized subpopulations upon chronic exposure to pathological beta-amyloid (Aβ) in AD mouse models (Keren-Shaul et al., 2017; Krasemann et al., 2017) , we sought to verify whether a similar phenotype may occur in xMGs. We, therefore, transplanted GFP + iHPCs into the newly developed 5X-MITRG mouse model (Methods) and allowed the mice to age for 9 months. Subsequent histological analysis revealed a clear and marked difference in the expression of numerous DAM markers in xMGs near Aβ plaques (Figure 7) . Similar to mouse DAMs and neurodegeneration-associated microglia (MGnDs), xMGs in contact with plaques downregulated the homeostatic marker P2RY12 (Figure 7A-H) , adopted an activated, ameboid morphology, and occasionally phagocytosed fibrillar Aβ (Video S3). Additionally, plaque-associated xMGs upregulated the DAM markers CD9 (Figure 7I-P Deletion of TREM2 consistently impairs the migration of murine microglia to A plaques (Jay et al., 2017; Ulrich et al., 2014; Wang et al., 2015; Wang et al., 2016) . Likewise, the ADassociated R47H mutation in TREM2 also impairs the association between microglia and plaques in AD subjects (Yuan et al., 2016) . To determine whether TREM2 plays a similar role in the migration of xMGs and to further test the utility of this model to study disease-relevant mutations, we transplanted 5x-MITRG mice with HPCs derived from isogenic CRISPR-edited iPSCs that carry either wild-type or R47H mutant TREM2. 9-months later, brains were examined by confocal microscopy and the association between plaques and XMGs examined by IMARIS 3D-quantification of confocal Z-stacks. As expected, this analysis revealed significantly less R47H xMGs clustering around Aβ plaques when compared to WT xMGs (Figure 7U-W) despite there being no significant difference in overall plaque burden across mice ( Figure 7X) . Taken as a whole, these data demonstrate that xMGs do, indeed, adopt relevant activation states in response to amyloid pathology and that the impact of diseaserelevant microglial mutations can be examined with this model.
Single-cell RNA-seq reveals transcriptomic alterations in response to AD pathology that are unique to human xMGs
While our histological analyses appeared promising, we sought to further characterize the xMG response to amyloid pathology at the transcriptomic level by isolating xMGs from the brains of aged MITRG (n=2) and 5X-MITRG (n=4) mice. Single-cell RNA sequencing (scRNAseq), performed utilizing the 10X genomics platform, resulted in 13,597 MITRG xMGs and 11,054 5X-MITRG xMGs. After quality filtering for doublets, damaged, and dividing cells, there were 10,184 MITRG and 8,673 5X-MITRG cells remaining with average UMI counts of 3,201 for MITRG and 3,242 for 5X-MITRG, and average genes per cell of 1,583 and 1,593, respectively.
Clustering of xMGs from both MITRG and 5X-MITRG mice (Figure 8A-B) , from both male and female mice (Figure S6A-B) , showed similar groups of MHC Class II cells (Orange; HLA-DRB1, HLA-DPB1, HLA-DQA1, and CD74), cells responding to Type I Interferon (Blue; IFI6, IRF7, ISG15, STAT1, and IFIT3), a group resembling murine DAMs (Salmon; CD9, TREM2, LPL, and ITGAX), as well as a cluster that was defined by a lack of the other cluster markers, which we deemed homeostatic (Green). Additionally, the MITRG xMGs displayed a cluster defined by high levels of inflammatory chemokines (Purple; CCL2, CXCL10, CCL8, and CXCL11) while the 5X-MITRG xMGs did not have a clearly defined chemokine cluster but, instead, displayed a cluster of cells defined by genes related to secretory function. Interestingly, canonical microglia markers (P2RY12, P2RY13, CX3CR1, and TMEM119) showed a relatively even distribution across most clusters, but decreased expression within the DAM clusters (Figure 8A-B, Figure S6C-D, Table S7 ). Additionally, despite general similarities between the clusters present in the MITRG and 5X-MITRG xMGs, differences existed in the proportion of microglia within each cluster (Figure 8C) , with the DAM and MHCII clusters being larger in the 5X-MITRG and the Interferon cluster being reduced.
We next sought to further examine the expression levels of AD risk genes within the 5X-MITRG xMGs. Analysis of expression levels of 50 AD risk genes revealed that 39 of these genes were expressed in at least one cluster and many were differentially expressed in specific clusters (FDR≤0.01; Figure S6E ). Furthermore, analysis of the amino acid homology of these genes demonstrated that a number of AD risk genes have problematic mouse homologs, with many mouse genes displaying low amino acid overlap and/or ambiguous gene homologs, and with CD33 lacking any reliable homolog in the mouse (Figure S6E) .
This observation led us to investigate whether the xMG approach was capable of revealing novel human-specific aspects of the microglia response to Aβ. To do so, we compared an xMG gene set, obtained by performing differential gene analysis between the DAM and homeostatic clusters in the 5X-MITRG, to the DAM genes published by Keren-Shaul et al. (2017) , as this was the most directly comparable study published to date. This comparison demonstrated that, while a number of highly expressed DAM genes showed overlap, there were a substantial number of both up and down regulated genes, 363 and 378 genes, respectively, that were unique to human xMGs (Figure 8D) . However, it is important to note that while the study published by Keren-Shaul et al. (2017) is the only currently published study examining the 5XfAD murine microglia response to Aβ pathology at the single-cell level, other studies have attempted to elucidate a similar phenotype via bulk sequencing, microarray, and qPCR in APP/PS1 and 5XfAD mice (Kamphuis et al., 2016; Krasemann et al., 9 2017; Yin et al., 2017) . Therefore, we also performed a comparison of our xMG DAM genes to an aggregated gene list composed of all the unique genes specified in these studies plus the Keren-Shaul study (Figure S6F; Table S7 ). While this comparison yielded slightly altered genes lists, there was still a high degree of discordance between the datasets, with 342 upregulated and 336 downregulated genes uniquely attributed to human xMGs.
In order to confirm that these differences were indeed relevant to the human microglial response to Aβ, we selected two genes, HLA-DRB1 and LGALS3, which have both been implicated in AD (Allen et al., 2015; Boza-Serrano et al., 2019) , for histological validation at the protein level in both xenotransplanted mice and AD-patient tissue. As shown in Figure  8E , both of these proteins are highly expressed in xMGs directly adjacent to murine Aβ plaques and this expression pattern bears a striking resemblance to the plaque-associated microglial labeling in AD-patient tissue. While an in-depth validation of all the unique xMG genes discovered in this analysis goes beyond the scope of the current article, this model clearly provides ample opportunity to investigate novel aspects of the in vivo microglial response to amyloid pathology. We, therefore, propose that xMGs are not just capable of recapitulating general in vivo microglia behavior, but that utilizing xMGs in conjunction with disease models provides a method of uncovering new genetic insights into human neurological disease.
Discussion
Over the last decade, the field has increasingly recognized the importance of microglia in both homoeostatic brain function and neurological disease. As our understanding has grown, so too has the need to develop more predictive models of human microglia to study these highly adaptable cells. Traditionally, this has meant collecting and culturing microglia from postmortem or surgically resected tissue or trusting that rodent microglia faithfully recapitulate human microglial phenotypes. While these approaches continue to be fundamental to our understanding of microglial biology, recent advancements have led to a more widely applicable toolkit. With the development of the first protocols to generate microglia from patient-derived stem cells in vitro, researchers are now able to model and manipulate the complex, polygenic landscapes that potentially underlie human microglia function and dysfunction. However, the field has also recently recognized that, despite these exciting new capabilities, the plasticity that makes microglia so fascinating represents a double-edged sword that complicates our attempts at in vitro modeling.
To address this challenge, we turned to transplantation of human iPSC-derived HPCs into the humanized, immune-deficient mouse brain. This paradigm induces robust microglial engraftment and differentiation of the complete complement of CNS macrophage subtypes. Additionally, microglia arising from this approach recapitulate the complex expression profile that is characteristic of their endogenous human counterparts, dynamically react to local and peripheral insults, and robustly respond to A pathology on both the morphological and transcriptomic levels. Taken together, these results support the conclusion that xMGs serve as suitable surrogates for endogenous human microglia, enabling new and informative in vivo studies of this important cell type.
Despite the many potential advantages of this chimeric model, it is important to note that xMGs expectedly come with caveats of their own, the most prominent being the requirement of an immune-deficient recipient organism. With recent studies demonstrating the interactive relationship between microglia and peripheral immune cells, especially in the context of neurodegeneration (Marsh et al., 2016) , this deficiency is important to acknowledge. While this problem is by no means unique to this model, as in vitro models inevitably suffer from the same pitfall, determining the most effective method of rectifying this shortcoming will require many additional studies.
Our hope is that the assessments herein provide a sufficient demonstration of the utility of this model that will encourage further studies examining the complex in vivo interactions between human microglia and neurological disease. The experiments utilizing the 5X-MITRG model and subsequent single-cell analysis of Aβ-exposed xMGs have already revealed a substantial genetic response that appears to be unique to human microglia. Additionally, our combination of this approach with an isogenic TREM2 mutant line, has highlighted the potential use of this model to interrogate the impact of individual risk genes on human microglia function. By leveraging CRISPR technology and the growing availability of patient iPSC lines, our hope is that this approach can be broadly used to examine the impact of mutations, genetic diversity, and polygenic risk on human microglial function and improve our understanding of these complex and fascinating cells.
Yin, Z., Raj, D., Saiepour, N., Van Dam, D., Brouwer, N., Holtman, I.R., Eggen, B.J.L., Moller, T., Tamm, J.A., Abdourahman, A., et al. (2017) . Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer's disease. Neurobiol Aging 55, 115-122. Yuan, P., Condello, C., Keene, C.D., Wang, Y., Bird, T.D., Paul, S.M., Luo, W., Colonna, M., Baddeley, D., and Grutzendler, J. (2016) . TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron 92, 252-264. Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Giron, C.G., et al. (2018) . Ensembl 2018. Nucleic Acids Res 46, D754-D761. overlying the hippocampus (Hip), xMGs exhibit a more elongated morphology with a diminished expression of P2YR12. (E-F) Consistent with normal anatomical distributions, xMGs also tend to avoid the granule cell layer of the dentate gyrus (GrDG) and the axonbundles within the striatum (STR). (G-H) Remarkably, xMGs also migrate to parts of the cerebellum (CRB) and spinal cord (SC). (I-L) A subset of GFP + cells exhibit an amoeboid morphology, linear organization, and lack the homeostatic microglia marker, P2RY12. These cells also encircle GLUT1 + blood vessels, localize to the perivascular space (J, K), and express CD163 (L) suggesting a perivascular macrophage (pvMϕ), meni ) phenotype. (M) Another population of GFP + /PU.1 + cells display robust engraftment in meningeal whole mounts. (N-O) These ameboid shaped meningeal macrophages (mMϕ), meni ) and can also be found in sections where parts of the meninges (MN) were preserved and are distinct from the fully ramified GFP + /hP2RY12 + microglia within the parenchyma (PAR). (P) Similar to the pvMϕ), meni , these mMϕ), meni are also GFP + /hP2RY12 -/CD163 + (arrows). (Q-T) A few GFP + /hP2RY12 -/CD163 + choroid plexus macrophage-like (cpMϕ), meni ) cells can be found within the choroid plexus (arrows). In some images, brightness and contrast settings were adjusted. Scale = 50m (A, D-J, N-Q, S, T), 25m (C, K), 20m (L), 100m (B, M, R).
Main Figure Titles and Legends
Figure 3. Transplantation of human iHPCs into the murine brain recapitulates an in vivo human transcriptome. (A)
PCA plot, including 16,413 genes, comparing freshly isolated human microglia (ExVivo, green; n=17 patients), xMGs (purple; 3 iHPC cell lines, n=3-6 mice per line, 13 mice total), iMGLs (yellow; n=6 wells), and cultured human microglia (InVitro, orange; n=13 patients) from our lab (MBJ, circles) or the Gosselin samples (triangles). ExVivo microglia and xMGs cluster together while both in vitro groups (iMGLs and InVitro) cluster separately. (B) PCA comparing the 3,432 differentially expressed genes between the Gosselin ExVivo and InVitro microglia (FDR=0.05, LFC cutoff=±2). Again, xMGs cluster closely with ExVivo microglia, demonstrating that transplantation recovered a braindependent microglia signature. (C) Heatmap comparing sample groups from our lab (MBJ, Blue) and Gosselin et al. (Red) based on the top 190 brain-dependent microglia signature genes. Euclidean clustering shows samples cluster by environment (in vivo or in vitro) and xMG samples are intermixed with ExVivo microglia samples. (D) xMGs express transcription factors at levels that are comparable to ExVivo microglia, many of which were either lowly or not expressed in vitro (red text). (E) xMGs express microglia signature genes and activation markers, including P2RY12, TGFB1, and CX3CR1, at comparable levels to ExVivo microglia, suggesting that xMGs have taken on a homeostatic transcriptomic profile. xMGs also express the brain-dependent microglial gene TMEM119, which was not previously expressed in iMGLs. (F) xMGs express AD risk genes at levels that coincide with non-AD ExVivo microglia. This finding demonstrates that xMGs could be accurate surrogates for AD studies in mouse models. Heatmaps in D-F represent VST normalized expression values, averaged for all samples in a group. (right) more clearly reveals the morphological dynamics of individual cells (also see Video S1). (B) The average length of extension/retraction in 5 minutes found in xMGs (3.73±0.10µm, n=300 observations, 3 mice) was not different from those found in mouse microglia (3.51±0.08µm, n=300 observations, 3 mice) (p=0.25, U=42581). (C) Time coded colorization of microglial response to focal damage reveals that processes rapidly move toward and surround the site of injury within 8 minutes post laser ablation. At later timepoints (t25-t35), some microglia outside the direct injury region translocate (white arrow), positioning their cell bodies closer to the injury (also see Video S2). (D) The mean intensity at the injury site (local, dark green) is higher than the mean intensity 150um away (distant, light green), showing that xMG processes rapidly localize to the injury site (repeated measures two-way ANOVA, p = 0.006. Scale = 50^m). (E) The average length of extension toward the ablation site in 10 minutes by xMGs (11.76±0.90µm, n=22 observations, 3 mice) is similar to those by mouse microglia (11.01±0.87µm, n=37 observations, 3 mice) (p=0.34, U=346). (F-G) Transplanted MITRG mice underwent repeat mild closed head injury (rmCHI) and histological analysis was (A) xMGs treated with saline exhibit strong staining for the homeostatic microglial protein P2RY12 (pseudocolored gray) and cytosolic GFP expression (green). In contrast, LPS-treated xMGs downregulate P2RY12, whereas GFP intensity increases along with distinct alterations in microglial morphology (Scale=50^m). (B) An upregulation of CD45 immunoreactivity (gray) can been seen after LPS treatment (Scale=50^m). (C) Quantification of GFP reveals a significant increase in intensity with LPS stimulation (p=0.0107) accompanied by a significant decrease in P2RY12 intensity (p=0.0003), and a significant increase in CD45 intensity (p=0.0004). (D) DGE analysis between microglia isolated from saline and LPS-treated animals revealed 607 upregulated genes (red, right) and 287 downregulated genes (blue, left) (FDR=0.01, LFC cutoff=±2; Table S4 ). Many upregulated genes (labeled, right) have been implicated in immune activation while a number of downregulated genes (labeled, left) have been described as markers of microglia homeostasis. (Blue; IFI6, IRF7, ISG15, STAT1, and IFIT3) , DAMs (Salmon; CD9, TREM2, LPL, and ITGAX), Inflammatory chemokines (Purple; CCL2, CXCL10, CCL8, and CXCL11), and a "homeostatic" cluster (Green) that was mainly defined by a lack of activation markers. Additionally, canonical microglia markers (P2RY12, P2RY13, CX3CR1, and TMEM119) showed a uniform distribution across all clusters besides DAMs. (B) tSNE plot of 8,673 xMGs isolated from 10.5 and 12-month-old 5X-MITRG mice (n=4) reveals similar clusters to the MITRG xMGs. Exceptions include the addition of a secretory cluster (Olive; ANAX3, AGR2, PLAC8, and PLA2G7) the loss of a clearly defined chemokine cluster. (C) Bar plot comparing the percentage of total cells making up each cluster in WT MITRG and 5X-MITRG tSNE plots. (D) DAM genes, reported by Keren-Shaul et al. (2017) , from 5XfAD murine microglia were filtered to contain only genes defined by Ensembl or NCBI Homologene to have 1:1 human orthologs. Remaining genes were then compared to the differentially expressed genes between DAM and homeostatic xMGs (FDR≤0.01) demonstrating that limited overlap exists between the human xMG and mouse DAM genes. (E) Protein-level validation of human-specific DAM genes HLA-DRB1 (top) and LGALS3 (bottom) in both 5X-MITRG and human AD brain sections. Figure 3 ) (A) Graphical overview of the transplantation and cell isolation workflow with up to 8 mouse brains being dissociated in parallel via enzymatic digestion on the Miltenyi gentleMACS OctoDissociator. Dissociated tissue is then separated from myelin and debris by centrifuging in 23% Percoll and the cell pellet is processed for flow cytometry. (B) Example gating strategy used during isolation of GFP + microglia from the mouse brain. Cells were first separated from debris via a liberal P1 gate. Doublets were then selected against in both the forward and side-scatter directions, followed by selection of the PI negative population (live cells), and conservative gating on the larger, brighter GFP + cells. A similar strategy was employed for isolation of non-GFP expressing human cells with final gating performed using human-specific HLA + and CD11b + antibodies. (C) GFP + human microglia are readily distinguished from mouse cells without additional fluorophores. (D) Initial validation of the HLA/CD11b staining paradigm consisted of identifying GFP negative human iMGLs mixed in a 9:1 (mouse:human) ratio with mouse BV2 microglia-like cells. (E) Subsequent, in vivo staining validation involved isolating transplanted non-GFP expressing human microglia from a dissociated mouse brain. (F) Negative staining control showing that there are no HLA/CD11b double-positive cells in a non-transplanted mouse brain. (G) Final validation of the HLA/CD11b isolation paradigm was performed on brains transplanted with GFP + human microglia. Applying a conservative gate based on FMO controls to the HLA/CD11b double-positive cells selects for a population that is 99.7% GFP+. (H) RNA-seq data on xMGs derived from 3 unique cell lines shows little to no contamination of transcripts that are typically associated with astrocytes (yellow), oligodendrocytes (orange), or neurons (purple), while microglia genes (light blue) are highly expressed, demonstrating successful isolation of a pure microglia population. Figure 3C ) according to the 190 brain-specific, microglia signature genes resulting from cross referencing the 3,432 brain-specific genes with the 881 gene signature from Gosselin et al. 2017 (Table S3 ). Note that samples are separated according to environment (in vivo vs in vitro) and xMG samples are interspersed with ExVivo microglia. (D) Heatmap displaying the 96 genes that are differentially expressed between xMGs and ExVivo samples (FDR<0.05; LFC=±2; Table S2 ) and also present in the Gosselin 881-gene signature. ExVivo samples collected from the three youngest patients (Table S1) False discovery rate (FDR) cutoffs of 0.25 (for hypothesis generation) and 0.05 (for validation) were applied. 23 downregulated pathways were significant at an FDR or 0.25 and only 1 was significant at the 0.05 cutoff. In contrast, 869 upregulated pathways were significant at an FDR≤0.25 and 112 were significant at an FDR≤0.05. (B) The top 70 GSEA pathways ordered by normalized expression score (NES) score and position in the list (ordered by NES). The pathways listed in C are identified by red dots and labels showing where each falls in the list. (C) A representative selection of pathways identified by GSEA. Identified pathways were highly related to metabolic processes, immune responses to bacteria, antigen presentation, and ribosomal/translational processes. The numbers shown within the bar graph indicate: # of genes mapped (# genes contributing to the enrichment score)/Total genes in the pathway; FDR. (D) Heatmap of the 96 microglia signature genes that were shown to be differentially expressed in xMGs. While LPS treatment did not fully recover these genes, a partial recovery of many genes related to immune activation, including many of the MHC Class II genes that were previously shown to be deficient in xMGs (red text), was observed following inflammatory insult. This finding may suggest that ExVivo human samples isolated from patients affected by epilepsy or collected from tumor margins may exhibit a partially activated state. (E) Figure 8B . (E) AD risk genes that are expressed at a minimum of 5% of cells in one cluster in the 5X-MITRG xMGs. The large boxes denote the percent homology between the amino acid sequences while the text within the large box denotes the human to mouse gene homology ratio (M=many genes). Gray boxes denote homology of less than 50%. Small boxes display which clusters expressed a given risk gene and the text denotes what percentage of cells in the cluster express the gene. Additionally, up and down arrows indicate that the gene was significantly up or downregulated, respectively, in a given cluster when compared to all other cells. (F) An aggregated list of unique genes, comprised of microglia AD response genes from four studies (Kamphuis et al., 2016; Keren-Shaul et al., 2017; Krasemann et al., 2017; Yin et al., 2017) (Table S7) , was filtered to contain only genes defined by Ensembl or NCBI Homologene to have 1:1 human orthologs. Remaining genes were then compared to the differentially expressed genes between DAM and homeostatic xMGs (FDR≤0.01) demonstrating that limited overlap exists between the transcriptomic response of human xMGs and mouse microglia to amyloid pathology.
Star Methods
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Mathew Blurton-Jones (mblurton@uci.edu).
Experimental Model and Subject Details Animals
All animal procedures were conducted in accordance with the guidelines set forth by the National Institutes of Health and the University of California, Irvine Institutional Animal Care and Use Committee. The MITRG mouse was purchased from Jackson Laboratories (stock #017711); this BALB/c/129 model includes two knockouts alleles, Rag2 -(Rag2 tm1.1Flv ), γc -(Il2rg tm1.1Flv ), and three humanized knock-in alleles, M-CSFh (Csf1 tm1(CSF1)Flv ), IL-3/GM-CSFh (Csf2/Il3 tm1.1(CSF2,IL3)Flv ), TPOh (Thpo tm1.1(TPO)Flv ). The related and parental M-CSFh mouse line was also purchased form Jackson Laboratories (stock # 017708) and contains Rag2 and Il2rg deletions and humanized M-CSFh. The 5xFAD-MITRG model was created by backcrossing the MITRG mouse with 5xFAD mice which overexpress co-integrated transgenes for Familial Alzheimer's Disease (FAD) mutant APP (Swedish, Florida, and London) and mutant FAD PS1 (M146L and L286V). Progeny of these pairings were then genotyped and backcrossed with MITRG mice to return the 5 MITRG genes to homozygosity and maintain the APP/PS1 transgenic loci in the hemizygous state, resulting in the MITRG5x (Rag2 -; γc -; M-CSF h ; IL-3/GM-CSF h ; TPO h ; Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas). To generate mice that lacked M-CSFh but included GM-CSFh and TPOh, MITRG mice were crossed with M-CSFh mice and then F1 progeny were crossed and genotyped to select mice that lacked either both or one copy of M-CSFh. For 2 photon living-imaging of mouse microglia, the CX3CR1-GFP (B6.129P2(Cg)-Cx3cr1 tm1Litt /J; stock # 005582) mouse was used. All mice were age and sex matched and group housed on a 12h/12h light/dark cycle with food and water ad libitum.
Acquisition and maintenance of iPSC lines iPSC lines were purchased from Coriell (AICS-0036 GFP line) and the European Bank for induced pluripotent Stem Cells (EBiSC, #BIONi010-C and #BIONi010-C-7). The GFP cell line (Coriell, AICS-0036) was generated by CRISPR modification of the line WTC11 to insert mEGFP into the AAVS1 safe harbor locus (chromosomal location 19q13.4-qter) under the control of a CAGG promoter. Additional information on this line can be found here: https://www.coriell.org/0/PDF/Allen/ipsc/AICS-0036-006_CofA.pdf. This line was chosen because the CAGG promoter has been previously shown to provide more consistent and prolonged expression in pluripotent stem cells and their derivatives when compared to the standard CMV promoters that are often prone to silencing (Liew et al., 2007) . We have found that GFP expression in this cell line remains robust for at least 12 months posttransplantation.
Maintenance of all iPSC lines involved culturing in feeder-free conditions in complete mTeSR E8 medium (Stemcell Technologies), in a humidified incubator (5% CO2, 37°C), with medium changed daily. Passaging was performed every 7-8 days using ReLeaSR (Stemcell Technologies) and cells were plated onto 6-well plates (Corning), coated with growth factorreduced Matrigel (1mg/mL; BD Biosciences), in mTeSR E8 medium, supplemented with 0.5uM Thiazovivin (Stemcell Technologies) for the first 24 hours post-passage.
Differentiation of Hematopoietic Progenitor Cells and in vitro Microglia from iPSCs
iHPCs and iMGLs were differentiated according to the protocol published by McQuade et al. (McQuade et al., 2018) . To begin HPC differentiation, iPSCs were passaged in mTeSR-E8 to achieve a density of 80 colonies of 100 cells each. On day 0, cells were transferred to Medium A from the STEMdiff™ Hematopoietic Kit (Stem Cell Technologies). On day 3, flattened endothelial cell colonies were transferred to Medium B and cells remained in medium B for 7 additional days while iHPCs began to lift off the colonies. On day 10, nonadherent CD43+ iHPCs were collected by removing medium and cells with a pipette. At this point, d10-d11 iHPCs can be frozen in Bambanker (Wako) and stored in liquid nitrogen at a concentration of 4 million cells/mL. Cells used for early-postnatal iHPC transplantation were thawed in iPS-Microglia media and allowed to recover for 24 hours, then resuspended at 62,500 cells/uL in 1X DPBS (low Ca 2+ , low Mg 2+ ). Cells utilized for in vitro experiments continued microglial differentiation by transferring non-adherent iHPCs to a Matrigel-coated 6-well plate containing microglial medium (DMEM/F12, 2X insulin-transferrin-selenite, 2X B27, 0.5X N2, 1X glutamax, 1X non-essential amino acids, 400 μM monôM monothioglycerol, and 5 μM monôg/mL human insulin) freshly supplemented with 100ng/mL IL-34, 50ng/mL TGFβ1, and 25 ng/mL M-CSF (Peprotech) for 28 days. During the last 3 days in culture, 100ng/mL CD200 (Novoprotein) and 100 ng/mL CX3CL1 (Peprotech) were added to mature microglia in a brainlike environment.
Method Details
Early Postnatal Intracerebroventricular Transplantation of iHPCs P0 to P1 MITRG mice were placed in a clean cage over a heating pad with a nestlet from the home cage to maintain the mother's scent. Pups were then placed on ice for 2-3 minutes to induce hypothermic anesthesia. Free-hand transplantation was performed using a 30-gauge needle affixed to a 10^L Hamilton syringe, mice received 1^L of iHPCs suspended in sterile 1X DPBS at 62.5K cells/^L at each injection site (8 sites) totaling 500K cells/pup. Bilateral injections were performed at 2/5 th of the distance from the lambda suture to each eye, injecting into the lateral ventricles at 3mm and into the overlying anterior cortex at 1 mm, and into the posterior cortex in line with the forebrain injection sites, and perpendicular to lambda at a 45° angle (Figure 1B) . Transplanted pups were then returned to their home cages and weaned at P21.
Adult intracranial transplants
All mouse surgeries and use were performed in strict accordance with approved NIH and AALAC-certified institutional guidelines. Direct bilateral intracranial injections of WT iMGL into the cortex and hippocampus were performed on adult MITRG mice. Briefly, adult mice (3 months old) were anesthetized under continuous isoflurane and secured to a stereotaxic frame (Kopf), and local anesthetic (Lidocaine 2%) was applied to the head before exposing the skull. Using a 30-guage needle affixed to a 10^L Hamilton syringe, mice received 2 ^L of mature iMGL suspended in sterile 1X DPBS at 50,000 cells/^L at each injection site. Transplantation was conducted bilaterally in the cortex and hippocampus at the following coordinates relative to bregma: anteroposterior, -2.06 mm; dorsoventral, -1.75 mm (hippocampus), -0.95 mm; mediolateral, ±1.75 mm. Cells were injected at a rate of 50,000/ 30s with 4min in between injections. The needle was cleaned with consecutive washes of PBS, 70% (vol/vol) ethanol, and PBS in between hemispheres and animals. Animals were allowed to recover on heating pads before being placed in their home cages and received 2 mg/mL Acetaminophen (Mapap) diluted in water for five days. Animals were perfused 2 months following surgery with 1X PBS followed by 4% paraformaldehyde, entire brains were removed for immunohistochemistry.
Immunohistochemistry and Confocal Microscopy
Animals were administered Euthasol and monitored for loss of consciousness. Once animals no longer responded to toe pinch, mice were intracardially perfused with ice cold 1X DPBS. If xMGs were being isolated from ½ brains, the remaining half brain was drop fixed in 4% (w/v) PFA for 48 hours, otherwise, the mice were intracardially perfused with 4% PFA and postfixed for 24 hours. Samples were then cryoprotected in 30% (w/v) sucrose until the tissue sank in the solution. Brains were then cut either coronally or sagittally at a section thickness of 40um on a sliding microtome cooled to -79°C. Tissue sections were collected as freefloating sections in PBS with and 0.05% sodium azide. For staining, tissue was blocked for 1 hour in 1X PBS, 0.2% Triton X-100, and 10% goat or donkey serum. Immediately following blocking, sections were placed in primary antibodies diluted in 1X PBS and 1% goat or donkey serum and incubated overnight on a shaker at 4°C. Sections were then incubated in conjugated secondary antibodies for 1 hour, before washing and mounting on microscope slides. Immunofluorescent sections were then visualized and captured using an Olympus FX 1200 confocal microscope. In some cases, brightness and contrast settings of confocal images were slightly adjusted to reveal fine structures and morphology. Importantly, no such changes were made to any images used for quantification. enrichment statistic. The gene list was compared to MSigDB's gene ontology database (c5.all.v6.2.symbols.gmt) consisting of the entire set of Gene Ontology terms (Ashburner et al., 2000; The Gene Ontology, 2017) and results were output, excluding any gene sets less than 15 genes or more than 5000 genes in length.
Gene Ontology Analysis
Gene ontology (GO) analysis was performed using PANTHER (Mi et al., 2017) . Upregulated (log fold change >= 2) or downregulated (log fold change <= -2) genes were compared to genes with a log fold change between 2 and -2 using a statistical overrepresentation test. Significantly (p<0.05) overrepresented GO terms were clustered and visualized using the EnrichmentMap plugin (Merico et al., 2010) in Cytoscape 3.6.1 (Shannon et al., 2003) .
Transcription Factor Binding Prediction and Co-Occurrence
Potential transcription factor binding sites were identified by searching the region 500bp upstream of genes using FOCIS (Webster, 2013) for binding motifs from the JASPAR database (2018 release) (Khan et al., 2018) . Upregulated (log fold change >= 2) or downregulated (log fold change <= -2) genes were compared to genes with a log fold change between 2 and -2 as background. Transcription factors with putative binding sites upstream of the same gene were considered to be co-occurring. Co-occurrence frequency of a transcription factor pair was described using the Jaccard index.
Literature search
Pubmed searches were performed using the term "microglia" or "Alzheimer" plus the name of each differentially expressed gene and transcription factor of interest. At least one publication result matching both terms was considered a positive result.
Statistical Analysis
All statistical analyses were performed in either R programming language or utilizing GraphPad Prism
Data and Software Availability
The raw and analyzed FASTQ files have been deposited in GEO. Accession number pending. Tables Titles and Legends   Table S1 . RNA-seq sample information (Related to Figure 3, Figure 5, and Figure  6 ). Figure 3) . Table S3 . DGE analysis related to microglia signature gene lists (Related to Figure  3) . Video S1. In vivo, 2-photon recording of homeostatic xMGs (Related to Figure 4) . Figure 4) . Figure 5 ). Figure 5 ). Figure 6 ). Figure 7) . Diagram comparisons (Related to Figure 8 ).
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